Navigation Links
Champalimaud Foundation Unveils C-TRACER in Hyderabad, India
Date:1/29/2008

Center to Utilize Stem Cells in Fight Against Blindness

HYDERABAD, India, Jan. 29 /PRNewswire/ -- The Champalimaud Foundation, one of the largest scientific foundations in the European Union, has announced the inauguration of the Champalimaud Center of Translational Eye Research (C-TRACER). The official ceremony will be January 30, 2008 in Hyderabad, India, and will attended by some of the most recognized vision experts and practitioners from Australia, India, the EU, and the U.S., as well as patients who have had their vision restored by the techniques that C-TRACER will utilize throughout the developing world.

C-TRACER is the result of an historic agreement between the Champalimaud Foundation and the LV Prasad Eye Institute (LVPEI), one of the foremost translational vision research centers in the world. One of only three places in the world which utilizes such techniques, the Institute uses stem cell science in the treatment of blindness, a cutting-edge technique that enables eye doctors to take cells from living adults and use them to grow the outer part of corneas. In one of the most revolutionary procedures in medical science today, doctors at the Institute have also begun using stem cells from the lip to produce corneas for implantation into the blind patient to restore sight.

C-TRACER will focus on the following areas: Research and therapy through the utilization of stem cells in vision-related illnesses; translational research utilizing existing and novel clinical methodologies, with the objective of furthering the knowledge of vision in such a way that it can be readily applied to the patient; exchange programs involving scientists chosen by the LVPEI and the Champalimaud Foundation; and, introduction of "capacity building" programs within Lusophone and other developing countries. In this way, C-TRACER will export the scientific model, thereby demonstrating a major goal of the program: to give new hope to the millions of blind people in the world today.

"With C-TRACER, the Champalimaud Foundation demonstrates its commitment to narrowing the gap between medical and scientific research and its practical applications," said Leonor Beleza, president of the Champalimaud Foundation. "This partnership with the LVPEI is a major step in the quest to eradicate world blindness through multilateral collaboration with some of the world's most prominent researchers and practitioners."

About the Champalimaud Foundation

The Champalimaud Foundation was created in 2004 at the bequest of the late Portuguese industrialist and entrepreneur Antonio de Sommer Champalimaud. With a 500 million endowment, it is one of the largest private foundations in Europe devoted to science. The Foundation is committed to supporting cutting- edge developments in medical science in the fields of vision, neuroscience, and oncology.

NOTE: High-resolution photos, B-Roll, and access to physicians and patients are available upon request.


'/>"/>
SOURCE The Champalimaud Foundation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. GeneGo and the Cystic Fibrosis Foundation Collaborate to Advance Understanding of Cystic Fibrosis
2. More Than 230 Cyclists to Ride in Amgen California Coast Classic Bike Tour to Raise $1.3 Million for Arthritis Foundation
3. International Atomic Energy Agency and National Foundation for Cancer Research Launch Major Initiative to Improve Cancer Prevention and Treatments in Developing Countries
4. Melanoma Research Foundation and Seattle Cancer Care Alliance Host Educational Symposium and Reception for Melanoma Patients, Family Members and Healthcare Providers
5. Foundation for Biomedical Research Board Chairman Awarded Congressional Gold Medal
6. The Parkinsons Disease Foundation Commemorates its 50th Anniversary with Special Scientific Symposium on Parkinsons Disease
7. Rutgers physicist earns prestigious Packard Foundation Science and Engineering Fellowship
8. Agendia BV Announces That its Chief Research Officer Laura van t Veer has Received a 2007 Breast Cancer Research Foundation Award
9. John Timberlake, Valeritas Executive Vice President and General Manager, Named Executive of the Year by the Diabetes Foundation
10. Genasense(R) Triple Combination Therapy in Advanced Melanoma Presented at Chemotherapy Foundation Symposium
11. eHealth Initiative Foundation Launches Collaborative Research Effort to Improve Drug Safety
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... Mass. , Jan. 18, 2017 ... applying mechanistic modeling to drug research and development, ... PhD, Co-Founder, President, and CEO of Applied BioMath, ... for Informatics and Modeling (BAGIM) Meeting on Thursday ... Cambridge , MA.   Dr. Burke,s ...
(Date:1/18/2017)... ... 2017 , ... Whitehouse Labs has furthered its efforts towards ... (AMRI), the scientific staff dedicated to Extractables / Leachables & Impurities has more ... 2017. Extractable & Leachable evaluations have become increasingly more vital to successful product ...
(Date:1/18/2017)... ... January 18, 2017 , ... DrugDev ... Summit for Clinical Ops Executives (Hyatt Regency Miami, January 24-26). DrugDev will join ... clinical research issues such as trial performance metrics, patient enrollment diversity, protocol optimization, ...
(Date:1/18/2017)... Shareholder rights law firm Johnson & Weaver, ... members of CoLucid Pharmaceuticals, Inc. (NASDAQ: CLCD ... proposed sale of the Company to Eli Lilly and ... molecules for the acute treatment of migraines. ... a definitive merger agreement with Eli Lilly. Under the ...
Breaking Biology Technology:
(Date:1/13/2017)... , Jan. 13, 2017 Sandata Technologies, ... for the homecare industry, including Electronic Visit Verificationā„¢ ... expert, Justin Jugs, as Senior Vice President of ... 15 years of homecare experience to Sandata, where ... strategic plans to align Sandata,s suite of solutions ...
(Date:1/12/2017)... Oregon and PUNE, India , January 12, 2017 /PRNewswire/ ... Market: Opportunities and Forecasts, 2015 - 2022," projects that the global biometric technology market ... of 19.4% from 2016 to 2022. Continue Reading ... ... ...
(Date:1/6/2017)... 2017  Privately-held CalciMedica, Inc., announced that it ... of a novel calcium release-activated calcium (CRAC) channel ... Acute pancreatitis, sudden painful inflammation of ... can be very serious.  In severe cases it can ... hospital stays, time in the ICU and substantial ...
Breaking Biology News(10 mins):